Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Gastroenterology. 2018 Aug 23;155(6):1985–1998.e5. doi: 10.1053/j.gastro.2018.08.028

Figure 2: Metavert significantly decreases pancreatic cancer cell survival and sensitizes cells to treatments without affecting normal cells.

Figure 2:

MIA PaCa-2 (A-B, D-F), BxPC-3 (A, C), HPAF-II (B) and HPDE6 (B) cells were cultured for 72h with different doses of metavert. (A-D, F) Cell survival was measured by MTT assay. (E) Apoptosis was measured by assessing DNA fragmentation. (B) Cells were cultured in the presence of a combination of indicated doses of metavert or Tideglusib and Saha. (D) BxPC-3 cells were cultured with 2.4μM metavert for 24h, then exposed to 4Gy irradiation and cultured for another 72h. MIA PaCa-2 cells cultured with Gemcitabine (Gem) 1ng/ml and metavert (150nM) (E) or 600nM (F) for 72h. *, p < 0.05 versus control; #, p < 0.05 versus the same dose of the combination of Tideglusib and Saha (B) or versus irradiation or chemotherapy treatment (C-F). Dashed lanes represent the expected additive effect.